Metformin Orifarm (Metformin Hydrochloride)

Metformin lowers blood sugar by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and increasing peripheral insulin sensitivity. These actions are mediated primarily through activation of the AMP‑activated protein kinase (AMPK) pathway.

The appropriate dose of Metformin Orifarm is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for Metformin Orifarm in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative treatments when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin Orifarm belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and weight‑neutral profile. Compared with sulfonylureas or insulin, it does not stimulate insulin release and has a different side‑effect spectrum.

Metformin Orifarm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme heat to maintain its stability and potency.

Metformin Orifarm is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or dissolving unless specifically instructed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin Orifarm is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those receiving iodinated contrast media without adequate renal monitoring.